Anthony J. Busti, MD, PharmD, MSc, FNLA, FAHA
EDUCATION:
Masters of Science in Evidence-Based Health Care (MSc)
University of Oxford
Oxford, UK
10/2015 - 10/2019
Emergency Medicine Residency
Johns Hopkins University School of Medicine
Johns Hopkins Hospital
Baltimore, MD
7/2012 - 6/2016
Doctor of Medicine (MD)
Texas A&M Health Science
Center College of Medicine
College Station, Texas
08/2008 - 05/2012
Post-Doctoral ASHP Accredited Clinical Pharmacy Residency
The University of Texas at Austin, College of Pharmacy
Austin, TX
Scott & White Memorial Hospital/Texas A&M University
Graduate Medical Education Program
Temple, TX
Doctor of Pharmacy (PharmD)
Texas Tech University Health Sciences Center
School of Pharmacy
Amarillo, TX
08/1997 - 05/2001
Valedictorian
Bachelors of Science in Nursing (BSN)
University of the Incarnate Word
San Antonio, TX
12/1993 - 12/1996
FELLOWSHIPS & BOARD CERTIFICATION:
Fellow, American Heart Association (FAHA)
Fellow, National Lipid Association (FNLA)
Diplomate, Accreditation Council for Clinical Lipidology
ACADEMIC EXPERIENCE:
Clinical Assistant Professor
UT Southwestern Medical School
Department of Emergency Medicine
Dallas, TX
07/2016 - Present
Attending Physician
Parkland Hospital
Dallas, TX
07/2016 - Present
Adjunct Faculty
Texas Woman's University
Graduate Nursing Program
Denton, Dallas, & Houston, TX
08/2003 - Present
Associate Professor
Texas Tech University Health Sciences Center (TTUHSC)
School of Pharmacy Dallas Fort Worth Regional Campus
Dallas, TX
08/2007 - 08/2008
Assistant Professor
Texas Tech University Health Sciences Center (TTUHSC)
School of Pharmacy Dallas Fort Worth Regional Campus
Dallas, TX
07/2002 - 07/2007
Invited Faculty
NIH Clinical Scholars Program
University of Texas Southwestern Medical School
Dallas, TX
01/2006 - 05/2008
Adjunct Professor
Graduate Nursing Program
Baylor University
Dallas, TX
08/2005 -12/2012
Clinical Instructor
Department of Pharmacy Practice
University of Texas at Austin
College of Pharmacy
Austin, TX
PROFESSIONAL EXPERIENCE:
Gubernatorial Member, Pharmaceutical & Therapeutics Committee
Health & Human Services Commission
Austin, TX
Appointed by: Governor Rick Perry
Chairman, Drug Utilization Review Board
State of Texas Health & Human Services Commission
Austin, TX
Appointed by: Executive Commissioner Albert Hawkins and Charles Bell, MD
Board of Governors
Accreditation Council for Clinical Lipidology (ACCL)
Board Member
National Lipid Association (NLA)
Jacksonville, FL
PUBLICATIONS:
Chow D, Koletar S, Glesby MJ, Busti AJ, Souza S for ACTG5209 Team. The Safety, Efficacy, and Tolerability of Ezetimibe in Combination with Statin Therapy for the Treatment of Elevated Non-HDL Cholesterol in HIV-Infected Subjects: ACTG (A5209) Trial [Original Research]. AIDS 2009;23(16):2133-41.
Mathys M, Blaszczyk A, Busti A. Incidence of abnormal metabolic parameters and weight gain induced by atypical antipsychotics in elderly patients with dementia. Consult Pharm 2009;24(3):201-9.
Alvarez CA, Russell NM, Edwards KL, Greene RS, Chastain LM, Weideman RA, Busti AJ. Combination thiazolidinedione and fibrate effect on high-density lipoprotein cholesterol (HDL-C) concentration in a Veterans Affairs patient population. J Clin Lipidology 2008;2:447-552.
Nguyen ST, Bain AM, Bedimo RG, Hall RG, Busti AJ (senior author). Rapid elevation of triglycerides after initiation of fosamprenavir/ritonavir in an HIV-negative patient with baseline hypertriglyceridemia. J Clin Lipidology 2008;2:398-400.
Busti AJ, Bain AM, Hall RG, Bedimo RG, Meek C, Leff R. The effect of atazanavir/ritonavir and fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin [Original Research]. J Cardivasc Pharmacol 2008;51(6):605-610.
Rahman AP, Eaton SA, Nguyen ST, Bain AM, Payne KD, Bedimo RG, Busti AJ (senior author). The lipid lowering effects of simvastatin in NNRTI-based HAART regimens in HIV-infected patients compared to non-HIV-infected patients [Original Research]. Pharmacotherapy 2008;28(7):913-9.
Bain AM, White E, Rutherford S, Rahman AP, Busti AJ (senior author). Treatment of antiretroviral-associated dyslipidemia: utilizing a multi-modal, evidence-based approach to achieve lipid targets. Case report and mini-review. Pharmacotherapy 2008;28(7):932-8.
Hall RG, Payne KD, Rahman AP, Bain AM, Nguyen ST, Eaton SA, Busti AJ. A multicenter evaluation of vancomycin dosing in tertiary medical centers [Original Research]. Am J Med 2008;121(6):515-8.
Busti AJ, Bedimo R, Margolis DM, Hardin D. Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated patients after switch to atazanavir/ritonavir (ATV/RTV): A prospective study using hyperinsulinemic, euglycemic clamp testing [Original Research]. J Investig Med 2008;56(2):539-44..
Nguyen ST, Eaton SA, Bain A, Payne K, Rahman A, Herrington J, Maclayton D, Rodriguez-Barradas M, Busti AJ (senior author). The lipid lowering efficacy and safety after a switch to an atazanavir/ritonavir based HAART in HIV-infected patients: a multi-center retrospective study [Original Research]. Pharmacotherapy 2008;28(3):323-330.
Bain AM, Payne KD, Rahman AP, Bedimo RG, Maclayton D, Rodriguez-BarradasM, Busti AJ (senior author). The lipid lowering efficacy of switching within non-nucleoside reverse transcriptase inhibitors in HIV-infected patients [Original Research]. Am J Infect Dis 2008;4(2):147-151.
Eaton SA, Rahman AP, Bain AM, Nguyen ST, Payne, KD, Busti AJ (senior author). Efficacy of pravastatin in non-nucleoside reverse transcriptase inhibitor (NNRTI) and protease inhibitor (PI)-based HAART in HIV-infected patients [Original Research]. Am J Infect Dis 2008;4(2):124-130.
Chastain L, Bain A, Edwards K, Bedimo R, Busti AJ (senior author). A retrospective study of the lipid lowering efficacy and safety of ezetimibe added to HMG-CoA reductase therapy in HIV-infected patients with hyperlipidemia [Original Research]. J Clin Lipidology 2007;1:634-639.
Hedges S, Dehoney S, Hooper J, Amanzadeh J, Busti AJ (senior author). Evidence based treatment recommendations for uremic bleeding. Nat Clin Pract Nephrol 2007;3(3):138-153.
Cole J, Busti AJ, Kazi H. The effect of TNF-a inhibitors on the incidence of new heart failure and exacerbation of existing heart failure in patients with rheumatoid arthritis [Original Research]. Rheumatol Int 2007;27(4):369-73.
Motsko SP, Rascati KL, Barner JC, Busti AJ, Lawson KA, Wilson JP. The relationship between COX-2 inhibitors and cardiovascular risk using the veteran's affairs (VA) database [Original Research]. Drug Safety 2006;29(7):621-632.
Busti AJ, Tsikouris JP, Peeters MJ, Das SR, Canham RM, Abdullah SM, Margolis DM. A prospective evaluation of the effect of atazanavir on the QTc-interval and QTc-dispersion in HIV-positive patients [Original Research]. HIV Med 2006;7:317-22.
Busti AJ. Appropriate use of statins with antiretrovirals. Are we making improvements? [Invited Commentary]. Contagion. November 2005; 2(11):1-4.
Busti AJ, Hooper JS, Amaya CJ, Kazi S. The influence of anti-inflammatory agents on wound healing in the post-surgical patient. Pharmacotherapy 2005;25(11):1566-1591.
Busti AJ, Hall RG, Margolis DM. Review: atazanavir (Reyataz®) for the treatment of HIV infection. Pharmacotherapy 2004;24(12): 1732-1747.
Busti AJ. Additional antiretroviral and immunosuppressive drug-drug interactions [letter]. Kidney International 2004;66(6):2469.
Busti AJ, Murillo JR, Cryer B. Tegaserod -induced myocardial infarction: Case report and hypothesis - an alternative viewpoint [reply]. Pharmacotherapy 2004;24(11):1649-1650.
Busti AJ, Bussey HI. The role of oral direct thrombin inhibitors in the treatment of venous thromboembolism. Pharmacotherapy 2004;24(10 Pt 2):184S-189S.
Busti AJ. Emerging and new therapies for venous thromboembolism. Anticoagulation Digest 2004;1(3):3-7.
Busti AJ, Marshall KS, Hooper JS. Reteplase in acute myocardial infarction [letter]. JAMA 2004;291(20):2429-30.
Hooper JS, Busti AJ. Ranolazine as add-on therapy for patients with severe chronic angina [letter]. JAMA 2004;291(16):1959.
Busti AJ, Murillo J. Cryer B. Tegaserod-induced myocardial infarction: case report and hypothesis. Pharmacotherapy 2004;24(4):526-531.
Busti AJ, Vervan M, Brouse S. Prednisone for chronic obstructive pulmonary disease [letter]. N Engl J Med 2003;349(13):1288-1290.
Books
Nuzum DS, Busti AJ. The 200 Drugs Review: What Every Clinician Must Know for Board Exams and Clinical Practice. Pharmacology Weekly, Inc. Texas. 2010.
Busti AJ (contributing author). In: Field JM, Bresler MJ, Kudenchuk PJ, Mattu A, O'Connor R, Silvers SM, VandenHoek T. The Textbook of Emergency Cardiovascular Care and CPR. . Lippincott Williams & Wilkins. 2008.
Busti AJ (contributing author). Advanced Cardiovascular Life Support. In: Hazinski MF, Field JM, Gilmore D, eds. Handbook of Emergency Cardiovascular Care for Healthcare Providers. Dallas, Texas: American Heart Association. 2008:1-98.
Davidson MH, Busti AJ, Cziraky MJ. National Lipid Association Self-Study Module: Module 2 Lipid-Altering Drug Pharmacology and Safety. Jacksonville, FL. National Lipid Association. December 2007.
Busti AJ (contributing author). In: ACLS Subcommittee 2006-2007, eds. ECG & Pharmacology Student Workbook. Dallas, Texas: American Heart Association. October 2007.
Busti AJ (contributing author). In: Ralston M, Hazinski MF, Zaritsky AL, Schexayder SM, Kleinman ME, eds. Pediatric Advanced Life Support. Provider Manual for Professionals. Dallas, Texas: American Heart Association. 2006.
Busti AJ (contributing author). In: Ralston M, Hazinski MF, Zaritsky AL, Schexayder SM, Kleinman ME, eds. Pediatric Advanced Life Support. Course Guide for Professionals. Dallas, Texas: American Heart Association. 2006.
Busti AJ (contributing author). In: Field JM, Gonzales L, Hazinski MF, eds. Advanced Cardiac Life Support Provider Manual for Professionals. Dallas, Texas: American Heart Association. 2006.
Busti AJ (contributing author). Advanced Cardiovascular Life Support. In: Field JM, Gilmore D, Hazinski MF, eds. Handbook of Emergency Cardiovascular Care for Healthcare Providers. Dallas, Texas: American Heart Association. 2006:5-70.
Busti AJ (contributing author). Advanced Cardiovascular Life Support Drugs and Electrical Therapy. In: Hazinski MF, Cummins RO, Field JM, eds. Handbook of Emergency Cardiovascular Care for Healthcare Providers. Dallas, Texas: American Heart Association. 2004:52-71.
PROFESSIONAL PRESENTATIONS:
International
Busti AJ, Bedimo R, Margolis D, Hardin D. Improvement in Insulin Sensitivity and Dyslipidemia in Protease Inhibitor-Treated Patients After Switch to Atazanavir/Ritonavir (ATV/RTV): A Prospective Study Using Hyperinsulinemic, Euglycemic Clamp Testing. 8th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. (Poster presentation). Sept 24 - 26, 2006; San Francisco, CA.
Motsko SP, Rascati KL, Barner JC, Busti AJ, Lawson KA, Wilson JP. Temporal Relationship between Non-steroidal anti-inflammatory drugs / COX-2 inhibitors and cardiovascular risk: a retrospective analysis using the veteran affairs (VA) database. 21st International Conference on Pharmacoepidemology and Therapeutic Risk Management (ISPE). Aug 21-24th, 2005, Nashville, TN, USA
Motsko SP, Rascati KL, Barner JC, Busti AJ, Lawson KA, Wilson JP. Association between long-term use of NSAIDS / COX-2 inhibitors and cardiovascular risk: a retrospective analysis using the veteran affairs (VA) database. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 10th Annual International Meeting. May 15-18, 2005, Washington, DC, USA.
National
Busti AJ. Pharmacology Program: Hypertensive Urgency and Emergency. American College of Cardiology 63rd Annual Scientific Sessions. Washington, DC. Invited Faculty. March 29, 2014
Busti AJ, Medley DB, Morris JE, Mower M, Shields J, Song J. Arrival by ambulance is significantly associated with violence toward staff in the emergency department. Scientific Assembly. American College of Emergency Physicians (ACEP). San Francisco, CA. October 15-18, 2011.
Bain AM, Busti AJ, Hall RG, Bedimo R, Leff R, Meek C, Mehvar R. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. [invited podium presentation]. 2008 National Lipid Association Annual Scientific Sessions. May 29 - June 1, 2008, Seattle, WA.
Busti AJ. The Role of a Pharmacist in Thyroid Disease. National Community Pharmacists Association Annual Meeting; invited faculty]. October 16, 2007, Anaheim, CA.
Bain A, Payne K, Rahman A, Bedimo R, Maclayton D, Rodriguez-Barradas M, Busti AJ. A multi-center retrospective study of the lipid lowering efficacy and safety of switching within non-nucleoside reverse transcriptase inhibitors in HIV-infected patients (poster presentation). 2007 National Lipid Association Annual Scientific Sessions. May 31 - June 3, 2007, Scottsdale, AZ. Dr. Bain recipient of 2007 NLA Young Investigator Award - awarded at 2007 Scientific Sessions Meeting in Scottsdale, AZ
Busti AJ. Treating the Difficult Patient. HIV Associated Dyslipidemia [podium presentation; invited faculty]. 2007 National Lipid Association Annual Scientific Sessions. May 31 - June 3, 2007, Scottsdale, AZ.
Nguyen ST, Eaton SA, Bain A, Payne K, Rahman A, Herrington J, Maclayton D, Rodriguez-Barradas M, Busti AJ. A multi-center retrospective study on the clinical efficacy and safety on lipid lowering effects after a switch to an atazanavir/ritonavir based HAART regimen (poster presentation). 2007 National Lipid Association Annual Scientific Sessions. May 31 - June 3, 2007, Scottsdale, AZ.
Eaton S, Nguyen S, Rahman A, Busti AJ. The lipid lowering effects of pravastatin in NNRTI and PI-based HAART regimens in HIV-infected patients (poster presentation). 2007 National Lipid Association Annual Scientific Sessions. May 31 - June 3, 2007, Scottsdale, AZ.
Rahman A, Eaton S, Nguyen S, Bain A, Payne K, Bedimo R, Busti AJ. The lipid lowering effects of simvastatin in NNRTI-based HAART regimens in HIV-infected patients compared to non-HIV-infected patients (poster presentation). 2007 National Lipid Association Annual Scientific Sessions. May 31 - June 3, 2007, Scottsdale, AZ.
Bain A, Payne K, Rahman A, Bedimo R, Busti AJ. Preliminary results from a retrospective study of the lipid lowering efficacy and safety of switching within non-nucleoside reverse transcriptase inhibitors in HIV-infected patients. 2007 ACCP Spring Practice and Research Forum Meeting. April 21-25, 2007, Memphis, TN.
Chastain L, Bain A, Edwards K, Bedimo R, Busti AJ. A retrospective study of the lipid lowering efficacy and safety of ezetimibe added to HMG-CoA reductase therapy in HIV-infected patients with hyperlipidemia. 2007 ACCP Spring Practice and Research Forum Meeting. April 21-25, 2007, Memphis, TN.
Mathys M, Blaszczyk A, Busti AJ. Incidence of Abnormal Metabolic Parameters and Weight Gain Induced by Atypical Antipsychotics in Elderly Dementia Patients. College of Psychiatric and Neurologic Pharmacists 10th Annual Meeting. (Poster Presentation). April 15-18, 2007; Colorado Springs, CO.
Busti AJ. Improving Managed Care's Perspective on Metabolic Health: Contribution of Triglycerides to Outcomes. Dinner Symposium at Academy of Managed Care Pharmacy 19th Annual Meeting and Showcase April 13, 2007; San Diego, CA.
Nguyen ST, Eaton SA, Bain A, Payne K, Rahman A, Herrington J, Busti AJ. A retrospective study on the clinical efficacy and safety on lipid lowering effects after a switch to an atazanavir/ritonavir based HAART regimen [poster RP273]. 41st ASHP Midyear Clinical Meeting and Exhibition. December 3-7, 2006. Anaheim, Orange County, CA.
Busti AJ. Lipid Management Strategies in Special Populations: Patients with HIV related dyslipidemia [podium presentation; invited faculty]. 2006 Annual Scientific Sessions for the Southeast Lipid Association. August 11-13, 2006, Amelia Island Plantation, Amelia Island, FL.
Busti AJ. HIV related dyslipidemia & approaches to treatment [invited co-moderator and presenter]. 2006 Annual Scientific Sessions for the National Lipid Association. April 6-9, 2006, Boston, MA.
Cox CD, Stanford BL, Brouse S, Hasse K, Akins RL, Bowie VL. Tsikouris JP, Busti AJ, Shah S, Hall R, Burleson BB, Seifert CF. Validation of an experimental teaching peer assessment tool. American College of Clinical Pharmacy 2004 Annual Meeting; October 24-27, 2004, Dallas, TX.
Kazi S, Cole J, Busti AJ. An evaluation of new onset CHF and CHF exacerbations in rheumatoid arthritis patients receiving TNF-a antagonists in a Veterans Affairs medical center. ACR/ARHP 68th Annual Scientific Meeting October 16-21, 2004; San Antonio, Texas.
Cox CD, Stanford BL, Busti AJ, Shah S, Haase KK, Hall R, Akins RL, Tsikouris JP, Bowie VL, Brouse S, Seifert CF, Sterling T. Validation of an experiential teaching peer assessment tool [abstract 62]. 2004 Annual Meeting of the American College of Clinical Pharmacy; Dallas, Texas.
Busti AJ. The influence of arthritis medications on wound healing [Podium Presentation]. Presented at the 10th Annual Foot Care Symposium. San Antonio, Texas; July 18-20, 2002.
Busti AJ. Metered-dose inhaler technique in patients presenting to the emergency department. [Poster Presentation] Pharmacy Student Research Conference Western Region and the Merck Company Foundation; Denver, CO. 06/2000.
State Level
Busti AJ. Making CYP450, Drug Interactions & Pharmacogenetics Easy to Understand. TNP 26th Annual Conference. San Antonio, Texas. September 5, 2014.
Busti AJ, Medley DB, Morris JE, Morgan DL, Song J. arrival by ambulance is significantly associated with violence toward staff in the emergency department. [Poster presentation]. Texas College of Emergency Physicians (TCEP). Galveston, TX. April 28 - May 1, 2011.
Busti AJ. Updates in Pharmacology & Drug Therapy. Texas Clinical Nurse Specialist 2011 Conference. Austin, TX. April 15-16, 2011.
Busti AJ. Heart Failure: Burden of Illness, Treatment Options, and the 2005 AHA/ACC Guidelines. Texas Society of Health-System Pharmacists' 60th Annual Seminar. Dallas, Texas. April 3-7, 2008.
Busti AJ. Drug Transporters and Phase II Metabolism: Their future role in drug-drug interactions. Texas Society of Health-System Pharmacists' 60th Annual Seminar. Dallas, Texas. April 3-7, 2008.
Payne K, Rahman A, Bain A, Nguyen S, Eaton S, Busti AJ, Hall RG. A multicenter retrospective evaluation of vancomycin dosing in tertiary medical centers. 21st ALCALDE Southwest Leadership Conference. April 19-20, 2007, San Antonio, TX.
Muldrew K, LaFrance B, Brouse SD, Busti AJ, Goodwin J. Pharmacist impact on adherence to ACLS guidelines and patient outcomes. 21st ALCALDE Southwest Leadership Conference. April 19-20, 2007, San Antonio, TX.
Acute & Chronic CV Risk Stratification and Early Use of Statins in ACS. Invited presentation at the Texas Society of Health-System Pharmacists, 58th Annual Meeting. Galveston, Texas; April 2, 2006.
Updates to the Adult ACLS Guidelines. Invited presentation at the Texas Society of Health-System Pharmacists, 58th Annual Meeting. Galveston, Texas; April 2, 2006.
Cardiovascular Health. Invited presentation at the Texas Pharmacy Association Annual Meeting. San Antonio, TX. July 7-10, 2005.
Immunology Update. Invited presentation at the Texas Pharmacy Association Annual Meeting. San Antonio, TX. July 7-10, 2005.
Gastroesophageal Reflux Disease: An Update on Treatment. Invited presentation at the East Texas Education Fair; Texas Pharmacy Association. Woodlands, Texas. April 22-24, 2005
Gastroesophageal Reflux Disease: An Update on Treatment. Invited presentation at the South Texas Education Fair; Texas Pharmacy Association. Corpus Christi, Texas. February 5-6, 2005
Heart Failure: Burden of Illness, Treatment Options, and Guidelines. Invited presentation at West Texas Education Fair; Texas Pharmacy Association. November 6-7, 2004.
Chronic Heart Failure. Presented at North Texas Education Fair; Texas Pharmacy Association. September 25-26, 2004.
The Treatment of Psychiatric Disorders in Women - Pharmacology Review. 27th Annual Conference on Women's Health Care. The University of Texas Southwestern Medical Center, Department of Obstetrics and Gynecology. June 18, 2004.
The development of the first pharmacotherapy specialty residency in the Dallas/Fort Worth Metroplex. Presented at the TSHP Leadership Development Program; Texas Society of Health-System Pharmacists Annual Meeting 2004; Houston, TX. 04/2004.
A collaborative model for a Class D pharmacy for the provision of pharmaceutical care. Presented at the Texas Society of Health-System Pharmacists Annual Meeting 2003; Arlington, TX. 04/2003
An evaluation of HIV patients on antiretrovirals beign treated for hyperlipidemia and/or hyperglycemia according to national guidelines. ALCALDE Southwest Residency Conference; Corpus Christi, TX. 04/2002.
A prospective analysis of patients with asthma or chronic obstructive lung disease on their use of inhalers when presenting to the emergency department. 2nd Annual Charles Marie Frank Lecture, UIW; San Antonio, TX. 04/2001
Local Level
Uremic Bleeding: Evidence Based Treatment Recommendations. Invited presentation at the Metroplex Society of Health-System Pharmacists Annual Convention. January 20, 2007.
An Update to the ACLS Guidelines. Invited presentation at the Metroplex Society of Health-System Pharmacists, 38th Annual Pharmacy Seminar Focus on USP 797 and IV Therapy. February 18, 2006.
A prospective evaluation of atazanavir's effect on QT dispersion in HIV infected patients. Podium presentation at TTUHSC School of Pharmacy Research Days Meeting. July 28-29, 2005; Amarillo, TX.
A Review in Pharmacotherapeutics. 8 hour CME program for nurses. Methodist Hospital; Dallas, TX. May 10, 2005
The Pharmacotherapy of Pain Management in the HIV Patient. 1 hour ACPE approved CME. VA North Texas Health Care System; Dallas, TX. 8/27/2003
A Review in Pharmacotherapeutics. 7 hour CME program for school nurses. Grapevine-Colleyville Independent School District; Grapevine, TX. 6/2003
Pain management in the HIV/AIDS patient. Presented at the 2002 HIV/AIDS Annual Seminar. Dallas, Texas; October 31, 2002.
A review of thrombus development and current treatment options. Department of Podiatric Medicine, Residency Conference, Texas A&M University Health Sciences Center; Temple, TX. 11/2001.
The use of ximelagatran (Exanta®) in patients undergoing total hip replacement or total knee replacement for the prevention of venous thromboembolism. Department of Surgery, Residency Conference, Texas A&M University Health Sciences Center; Temple, TX. 10/2001
